Inhibition of SHP2 has emerged as a promising approach to treat RTK-driven cancers (Chen et al., 2016), and to prevent adaptive resistance in RAS mutant cancers (Fedele et al., 2018). This evidence concerns the gene PTPN11 and cancer.